Molecular tests for tuberculosis (TB) have the potential to help reach the three million people
with TB who are undiagnosed or not reported each year and to improve the quality of care …

Mendelian and complex genetic trait diseases continue to burden and affect society both
socially and economically. The lack of effective tests has hampered diagnosis thus, the …

The World Health Organization's End TB Strategy prioritizes universal access to an early
diagnosis and comprehensive drug susceptibility testing (DST) for all individuals with …

Drug-resistant tuberculosis is a substantial health-care concern worldwide. Despite culture-
based methods being considered the gold standard for drug susceptibility testing, molecular …

Targeted next-generation sequencing (tNGS) has emerged as a comprehensive alternative
to existing methods for drug susceptibility testing (DST) of Mycobacterium tuberculosis from …

Antimicrobial resistance (AMR) has become a global medical priority that needs urgent
resolution. Pseudomonas aeruginosa is a versatile, adaptable bacterial species with …

Conventional molecular tests for detecting Mycobacterium tuberculosis complex (MTBC)
drug resistance on clinical samples cover a limited set of mutations. Whole-genome …

Global human health is increasingly challenged by emerging viral threats, especially those
observed over the last 20 years with coronavirus-related human diseases, such as the …

Clinical metagenomics is the diagnostic approach with the broadest capacity to detect both
known and novel pathogens. Clinical metagenomics is costly to run and requires …

Guidelines on the treatment of tuberculosis (TB) have essentially remained the same for the
past 35 years, but are now starting to change. Ongoing clinical trials will hopefully transform …